4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:原厂直采,平行进口,授权代理(蚂蚁淘为您服务)
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > juhewu > Sino Biological/SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein/1/40588-V08B
商品详细Sino Biological/SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein/1/40588-V08B
Sino Biological/SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein/1/40588-V08B
Sino Biological/SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein/1/40588-V08B
商品编号: 40588-V08B
品牌: sinobiological
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 聚合物
公司分类: juhewu
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: Product Information

Purity
> 90 % as determined by SDS-PAGE.
Endotoxin
< 1.0="" eu="" per="" μg="" protein="" as="" determined="" by="" the="" lal="">
Activity
Testing in progress
Protein Construction
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (YP_009724397.2(335Gly/Ala)) (Met1-Ala419) was expressed with a polyhistidine tag at the C-terminus.
Accession#
YP_009724397.2
Expressed Host
Baculovirus-Insect Cells
Species
2019-nCoV
Predicted N Terminal
Met 1
Molecule Mass
The recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (His tag) consists of 430 amino acids and predicts a molecular mass of 47.08 kDa.
Formulation
Lyophilized from sterile 20mM Tris, 500mM NaCl, pH8.0, 10%glycerolPlease contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: Images

2019-nCoV CoV Nucleocapsid Protein 29778

SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: Synonyms

coronavirus NP Protein, 2019-nCoV; coronavirus Nucleocapsid Protein, 2019-nCoV; coronavirus Nucleoprotein Protein, 2019-nCoV; cov np Protein, 2019-nCoV; ncov NP Protein, 2019-nCoV; NCP-CoV Nucleocapsid Protein, 2019-nCoV; novel coronavirus NP Protein, 2019-nCoV; novel coronavirus Nucleocapsid Protein, 2019-nCoV; novel coronavirus Nucleoprotein Protein, 2019-nCoV; np Protein, 2019-nCoV; nucleocapsid Protein, 2019-nCoV; Nucleoprotein Protein, 2019-nCoV

Coronavirus Nucleocapsid Background Information

Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The coronavirus N protein is required for coronavirus RNA synthesis and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is the most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to the formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of the N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
References
    1. 1.Van Boheemen S, et al. (2012),MBio. 3(6):e00473-12.
    2. Bisht H. et al., 2004,Proc Natl Acad Sci. 101 (17): 6641-6.
    3. Li W. et al., 2005,Science.309 (5742): 1864-8.

2019-nCoV Coronavirus Nucleocapsid Proteins

  • SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Recombinant Protein40588-V07E
  • SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein, Biotinylated40588-V08B-B
  • SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Recombinant Protein, Biotinylated40588-V07E-B
  • SARS-CoV-2 (2019-nCoV) Nucleocapsid-AVI & His recombinant Protein, Biotinylated40588-V27B-B

HCoV-OC43 Coronavirus Nucleocapsid Proteins

  • Human coronavirus (HCoV-OC43) Nucleoprotein / NP Protein (His Tag)40643-V07E

HCoV-NL63 Coronavirus Nucleocapsid Proteins

  • Human coronavirus (HCoV-NL63) Nucleoprotein / NP Protein (His Tag)40641-V07E

HCoV-229E Coronavirus Nucleocapsid Proteins

  • Human coronavirus (HCoV-229E) Nucleoprotein / NP Protein (His Tag)40640-V07E

SARS Coronavirus Nucleocapsid Proteins

  • SARS-CoV Nucleoprotein / NP Protein (His Tag)40143-V08B

HCoV-HKU1 Coronavirus Nucleocapsid Proteins

  • Human coronavirus (HCoV-HKU1) Nucleoprotein / NP Protein (His Tag)40642-V07E

MERS-CoV Coronavirus Nucleocapsid Proteins

  • MERS-CoV Nucleoprotein / NP protein (His Tag)40068-V08B
  • Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray
    Author
    De Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
    FoldedExpand
  • Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
    Author
    Khan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
    FoldedExpand
  • COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
    Author
    Randad, PR;Pisanic, N;Kruczynski, K;Manabe, YC;
    Year
    2020
    Journal
    medRxiv
    FoldedExpand
  • Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients
    Author
    Sun, B;Feng, Y;Mo, X;Zheng, P;Wang, Q;Li, P;Peng, P;Liu, X;Chen, Z;Huang, H;Zhang, F;Luo, W;Niu, X;Hu, P;Wang, L;Peng, H;Huang, Z;Feng, L;Li, F;Zhang, F;Li, F;Zhong, N;Chen, L;
    Year
    2020
    Journal
    Emerg Microbes Infect
    PubMed ID: 32357808FoldedExpand
  • SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity
    Author
    Phipps, WS;SoRelle, JA;Li, QZ;Mahimainathan, L;
    Year
    2020
    Journal
    medRxiv
    Application
    IgM testing
    FoldedExpand
  • Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection
    Author
    Simon, D;Tascilar, K;Krönk, G;Kleyer, A;Zaiss, M;Heppt, F;Meder, C;Atreya, R;Klenske, E;Dietrich, P;Abdullah, A;Kliem, T;Corte, G;Morf, H;Leppkes, M;Kremer, A;Ramming, A;Pachowsky, M;Schuch, F;Ronneberger, M;Kleinert, S;Maier, C;Hueber, A;Manger, K;Manger, B;Berking, C;Tenbusch, M;Überla, K;Sticherling, M;Neurath, M;Schett, G;
    Year
    2020
    Journal
    Research Square
    FoldedExpand
  • SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients
    Author
    Lei, H;Ye, F;Liu, X;Huang, Z;Ling, S;Jiang, Z;Cheng, J;Huang, X;Wu, Q;Wu, S;Xie, Y;Xiao, C;Ye, D;Yang, Z;Li, Y;Leung, NHL;Cowling, BJ;He, J;Wong, SS;Zanin, M;
    Year
    2020
    Journal
    Influenza Other Respir Viruses
    PubMed ID: 32578948FoldedExpand
  • SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence
    Author
    den Hartog, G;Schepp, R;Kuijer, M;GeurtsvanKessel, C;van Beek, J;Rots, N;Koopmans, M;van der Klis, F;van Binnendijk, R;
    Year
    2020
    Journal
    medRxiv
    FoldedExpand
  • COVID-19 Severity Correlates with Weaker T Cell Immunity, Hypercytokinemia and Lung Epithelium Injury
    Author
    Wang, Z;Yang, X;Zhou, Y;Sun, J;Liu, X;Zhang, J;Mei, X;Zhong, J;Zhao, J;Ran, P;
    Year
    2020
    Journal
    Am. J. Respir. Crit. Care Med.
    Application
    neutralization test
    PubMed ID: 32608999FoldedExpand
  • SARS-CoV-2 surveillance for a non-human primate breeding research facility
    Author
    Yee, JL;Van Rompay, KKA;Carpenter, AB;Nham, PB;Halley, BM;Iyer, SS;Hartigan-O"Connor, DJ;Miller, CJ;Roberts, JA;
    Year
    2020
    Journal
    J. Med. Primatol.
    PubMed ID: 32621339FoldedExpand
  • A rapidly adaptable biomaterial vaccine for SARS-CoV-2
    Author
    Langellotto, F;Seiler, B;Yu, J;Cartwright, M;White, D;Yeager, C;Super, M;Doherty, E;Barouch, D;Mooney, D;
    Year
    2020
    Journal
    bioRxiv
    FoldedExpand
  • Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunity
    Author
    McAndrews, KM;Dowlatshahi, DP;Dai, J;Becker, LM;Hensel, J;Snowden, LM;Leveille, JM;Brunner, MR;Holden, K;Hopkins, NS;Harris, A;Kumpati, JJ;Whitt, MA;Lee, JJ;Ostrosky-Zeichner, L;Papanna, R;LeBleu, V;Allison, J;Kalluri, R;
    Year
    2020
    Journal
    JCI Insight
    PubMed ID: 32796155FoldedExpand
  • Accurate Serology for SARS-CoV-2 and common Human Coronaviruses using a Multiplex Approach
    Author
    van Tol, S;Mögling, R;Li, W;Godeke, GJ;Swart, A;Bergmans, B;Brandenburg, A;Kremer, K;Murk, JL;van Beek, J;Wintermans, B;Reimerink, J;Bosch, BJ;Reusken, C;
    Year
    2020
    Journal
    Emerg Microbes Infect
    PubMed ID: 32819220FoldedExpand

If you couldn"t find the specific citation, you can:

  • Find All Citations
  • Submit a CitationGet a Publication Reward
  • Leave Us a Message

E.coli protein expression service

Mammalian transient protein expression service

Baculovirus-insect expression service

Stable cell line development service (CHO / HEK293)

品牌介绍
北京义翘神州科技股份有限公司(Sino Biological Inc.)是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司,主要业务包括重组蛋白、抗体、基因和培养基等产品,以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种,其中重组蛋白约 6,000 种,包括超过 3,800 种人源细胞表达重组蛋白产品,能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求;公司还能提供约 12,000 种抗体,其中单克隆抗体数量约 4,600 种,能够覆盖生命科学研究的多个领域,为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司,已成为生物试剂行业国内领先的科技公司之一。